

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: HU et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently Herewith

Examiner: To be assigned

For: Vascular Endothelial Growth Factor 2

Attorney Docket No.: PF112P3D1C1

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, Applicants respectfully request entry of the following amendments and remarks. Applicants submit herewith a Version With Markings Showing Changes Made.

Please amend the application as follows.

In the Specification:

At page 1, after the Title, please delete the first paragraph and insert therefor:

--This application is a continuation of U.S. Application No. 09/438,538, filed November 12, 1999, which is a division of U.S. Application No. 09/042,105, filed March 13, 1998, which is a continuation-in-part of U.S. Application No. 08/999,811, filed December 24, 1997 (now issued U.S. Patent No. 5,932,540), which is a continuation-in-part of both U.S. Applications Serial No. 08/465,968, filed June 6, 1995 and Serial No. 08/824,996 (now issued U.S. Patent No. 5,935,820), said 08/465,968 is a continuation-in-part and said 08/824,996 is a division of U.S. Application Serial No. 08/207,550, filed March 8, 1994 (now abandoned), all of which claim priority under 35 U.S.C. § 120, and all are hereby incorporated by reference in their entirety. --

In the Claims

Claims 28-31 and 74 have been amended as follows:

- 28. The isolated polypeptide of 25, which is antigenic.
- 29. The isolated polypeptide of claim 25, which promotes angiogenesis.
- 30. The isolated polypeptide of claim 25, which promotes epithelialization.
- 31. The isolated polypeptide of claim 25, which promotes vascularization.
- 74. An isolated polynucleotide encoding the polypeptide of claim 1.

Remarks


The specification has been amended to claim benefit of priority.

The claims have been amended to correct multiple claim dependencies and reduce the claim calculation fees.

No new matter has been added by way of this amendment.

[illegible]

Respectfully submitted,


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Enclosures

Appl. Serial No.: TBA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: HU et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently Herewith

Examiner: To be assigned

For: Vascular Endothelial Growth Factor 2

Attorney Docket No.: PF112P3D1C1

VERSION WITH MARKINGS SHOWING CHANGES MADE

In the Claims

Claims 28-31 and 74 have been amended as follows:

28. (Once Amended) The isolated polypeptide of 25 [or 26], which is antigenic.

29. (Once Amended) The isolated polypeptide of claim 25 [or 26], which promotes angiogenesis.

30. (Once Amended) The isolated polypeptide of claim 25 [or 26], which promotes epithelialization.

31. (Once Amended) The isolated polypeptide of claim 25 [or 26], which promotes vascularization.

74. (Once Amended) An isolated polynucleotide encoding the polypeptide of [claim 1, 7, 8, 21, 25, 26, 32, 42, 46, 47, 48, or 67] claim 1.